Trial shows immunotherapy drug Opdivo is safe, effective against Hodgkin lymphoma

The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, a new study shows.